Saha Somdutta, Rajpal Deepak K, Brown James R
Computational Biology, Target Sciences, R&D, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, USA.
Computational Biology, Target Sciences, R&D, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, PA 19426-0989, USA.
Drug Discov Today. 2016 Apr;21(4):692-8. doi: 10.1016/j.drudis.2016.02.009. Epub 2016 Feb 22.
Crosstalk between the microbiome and the human host is mediated by specific ligand-receptor interactions involving microbially generated metabolites that can be either agonists or antagonists of human proteins. The evolved co-compatibility of gut microbiota with human systems points to a potentially rich area for discovering new drug-like molecules that are both highly specific modulators of human pathways and derisked for adverse effects. In this review, we discuss the rapidly growing research into the role of microbial metabolites in human health and suggest potential strategies for developing these molecules into therapeutic agents.
微生物群与人类宿主之间的相互作用是由特定的配体-受体相互作用介导的,这些相互作用涉及微生物产生的代谢产物,它们既可以是人类蛋白质的激动剂,也可以是拮抗剂。肠道微生物群与人类系统进化而来的共同适应性,指出了一个潜在的丰富领域,可用于发现新的类药物分子,这些分子既是人类信号通路的高度特异性调节剂,又具有较低的不良反应风险。在这篇综述中,我们讨论了关于微生物代谢产物在人类健康中的作用的快速发展的研究,并提出了将这些分子开发成治疗药物的潜在策略。